ClinicalTrials.gg
Active, not recruitingNCT04232241Updated Apr 22, 2025

Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia

A Phase 2 interventional study of Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission and Myelodysplastic Syndromes, sponsored by Universitätsklinikum Hamburg-Eppendorf. Active, not recruiting at 24 sites in 7 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-04-22.

Sponsored by Universitätsklinikum Hamburg-Eppendorf · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
167
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 160 studies in Myelodysplastic Syndromes with a site in Germany — 16 open to participants now, 31 under way, 13 of them phase 3. Myelodysplastic Syndromes · Germany.

Enrollment
50th of 143
167 · median 87
Started
2019
with 6 others
Phase 2
56 of 160
5 open now
Primary completion
2026-11
later than 10 of 30 live
Registered
119th of 160
by date

Among the 160 studies in Myelodysplastic Syndromes with a site in Germany, this one is the 50th largest by enrollment of the 143 interventional ones that give a count, is one of 7 that started in 2019, is one of 56 in phase 2, reaches primary completion later than 10 of the 30 other live ones, and was the 119th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 318 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

16 of the 160 studies in Myelodysplastic Syndromes with a site in Germany are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 259 Myelodysplastic Syndromes studies recruiting now, 166 (64%) set no upper age limit and 67 (26%) stop at 75 or younger; 55 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 160 studies in Myelodysplastic Syndromes with a site in Germany, or all of them as a file.
02

Study summary

Primary objective of this open label, two-arm, multicenter, multinational, randomized trial is to compare anti-leukemic activity of allogeneic stem cell transplantation for patients with acute leukemia in complete remission between a 10/10 HLA matched unrelated donor and a haploidentical donor.

The hypothesis: Haploidentical stem cell transplantation with post cyclophosphamide induces a stronger anti-leukemic activity in comparison to 10/10 HLA matched unrelated donor and reduces the risk of relapse at 2 years after stem cell transplantation by 10%.

Read the detailed description

Secondary objectives are to assess and compare the safety and efficacy of study treatments therapy in both study arms on non-relapse mortality (NRM), relapse-free survival (RFS), Overall survival (OS), QOL, toxicity, development of acute and chronic GvDH as well as engraftment and chimerism and impact of measurable residual disease.

03

Conditions studied

  • Acute Myeloid Leukemia in Remission
  • Acute Lymphoblastic Leukemia in Remission
  • Myelodysplastic Syndromes

Keywords

  • Acute Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Myelodysplastic Syndromes
  • Allogeneic Stem Cell Transplantation
  • Matched Unrelated Allogeneic Stem Cell Transplantation
  • Haploidentical Allogeneic Stem Cell Transplantation
  • anti-leukemic activity
  • Cyclophosphamide as GVHD prophylaxis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Acute Myeloid Leukemia (AML) intermediate or high risk according to ELN or Acute Lymphoblastic Leukemia (ALL) high risk according to ESMO guidelines in 1. CR or AML/ALL in 2. CR, or high risk MDS (according to IPSS-R) in 1. CR or 2. CR.
  2. Patients age: 18 - 70 years at time of inclusion (female and male).
  3. Patients understand and voluntarily sign an form.
  4. ≤ 2.
  5. 10/10 HLA-matched unrelated donor and haploidentical (≥ 5/10 and ≤ 8/10 HLA) relative matched donor available at least 4 weeks after completion of induction and/or consolidation therapy.
  6. Females/Males who agree to comply with the applicable requirements of the protocol.

Exclusion criteria

Exclusion Criteria

  1. Severe renal, hepatic, pulmonary or cardiac disease, such as:

    • total , or SGOT > 3 times upper the normal level
    • \< 30 %
    • \< 30 ml/min
    • DLCO \< 35 % and/or receiving supplementary continuous oxygen
  2. Positive serology for .
  3. Pregnant or lactating women (positive serum pregnancy test).
  4. Age \< 18 and ≥ 71 years.
  5. Uncontrolled invasive fungal infection at time of screening (baseline).
  6. Serious psychiatric or psychological disorders.
  7. Participation in another study with ongoing use of unlicensed product from 28 days before study enrollment.
  8. Uncontrolled severe disease or uncontrolled other .
  9. Availability of an HLA-identical sibling as donor source.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
167 participants (actual)

Study arms

  • Active comparator
    Treatment A

    Allogeneic stem cell transplantation from 10/10 HLA matched unrelated donor

    Drug: Allogeneic Stem Cell Transplantation

  • Experimental
    Treatment B

    Allogeneic stem cell transplantation from haploidentical donor

    Drug: Allogeneic Stem Cell Transplantation

Interventions

  • DrugAllogeneic Stem Cell Transplantation

    Allogeneic Stem Cell Transplantation

06

What researchers measure

Primary outcomes

  1. Relapse incidence at two years between both arms

    The primary efficacy endpoint will be analyzed using cumulative incidence estimation to assess the subdistribution hazard rates for both treatment groups at two years after accounting for competing risk events.

    Time frame: 2 years

Secondary outcomes

  1. Overall survival at two years between both arms

    The overall survival at two years between both arms will be presented with Kaplan-Meier's estimates of survival.

    Time frame: 2 years

  2. Overall survival for all patients assigned to one of the two treatment arms as time to event endpoint

    The overall survival for all patients will be presented with Kaplan-Meier curve. To compare the survival distributions between two arms, log-rank test will be performed, and two-sided p-values will be presented. If applicable, Cox regression model stratified by the types of leukemia, types of complete remission and conditioning will be performed as sensitivity analysis.

    Time frame: through study completion, an average of two yeras

  3. Comparison of GVHD/relapse-free survival as Composite endpoint in both arms

    The rate of composite endpoint in both arms will be analyzed with the same methods as for the overall survival at two years between both arms.

    Time frame: Starting at day +30 (+/- 3 d) to 24 months (+/- 1 mo) after allogenic stem cell transplantation (SCT)

  4. Comparison of non-relapsed mortality (NRM) at 1 and 2 years after allogeneic SCT in both arms

    Due to the existence of competing risk events (persisting disease and relapse), NRM of each arm at 1 and 2 years after allogeneic SCT will be analyzed with the same methods as for the primary endpoint

    Time frame: At 1 and 2 years after allogeneic SCT

  5. Comparison of acute graft-versus-host disease (aGVHD) on day +100 and 1 year (max grade) after allogeneic SCT according to the Glucksberg scale revised by Przepiorka et al. between both arms

    For each time point, the frequency and percentage of aGVHD (maximum grade) of each arm will be presented. To compare the difference between both arms, logistic regression adjusted for covariates and stratification factors will be performed.

    Time frame: On day +100 and 1 year (max grade) after allogeneic SCT

  6. Comparison of chronic graft-versus-host disease (cGVHD) according to the NIH consensus criteria of Jagasia et al. at 1 and 2 years after allogeneic SCT between both arms

    For each time point, the frequency and percentage of cGVHD of each arm will be presented. To compare the difference between both arms, logistic regression adjusted for the stratification factors will be performed.

    Time frame: At 1 and 2 years after allogeneic SCT

  7. Comparison of toxicity of both regimens scored according to the current version of the NCI CTCAE between both arms

    Safety will be analyzed with frequency of patients with AEs as described above.

    Time frame: through study completion, an average of two yeras

  8. Comparison of immune reconstitution between both arms

    Frequency and percentage of patients having immune reconstitution in two arms will be provided. For the comparison between two arms, logistic regression adjusted for the stratification factors will be performed.

    Time frame: At day 30, 100, 6 months, 1 year and 2 years after allogenic SCT

  9. Comparison of full donor chimerism between both arms

    Frequency and percentage of patients having full donor chimerism in two arms will be provided. For the comparison between two arms, logistic regression adjusted for the stratification factors will be performed.

    Time frame: At day 30, 100, 6 months, 1 year and 2 years after allogenic SCT

  10. Evaluation of Sorror Risk Score on outcome after allogeneic SCT

    Comorbidity score after Sorror will be assessed prior to randomization and outcome in both arms will be analyzed according the pre-transplant Sorror score.

    Time frame: At baseline

  11. Comparison of QOL (FACT-BMT) before and after transplantation at + 100 days, 6 months, 1 year, 2 years between both arms

    The means of change in scores at each time point (day 100, 6 months, 1 year and 2 years after transplantation respectively) from baseline and the confidence intervals of each arm will be presented. To compare the difference in QOL scores between both arms, logistic regression adjusted for covariates and stratification factors will be performed for each time point.

    Time frame: At day 100, 6 months, 1 year and 2 years after allogenic SCT

Other outcomes

  1. Scientific Endpoint (optional)

    Comparison of relapse incidence at two years between MRD positive and negative patients in both arms

    Time frame: 2 years

  2. Scientific Endpoint (optional)

    Comparison of overall survival at two years between MRD positive and negative patients in both arms

    Time frame: 2 years

07

Study locations

24 sites
08

References and documents

Publications

  • Sanz J, Galimard JE, Labopin M, Afanasyev B, Sergeevich MI, Angelucci E, Kroger N, Koc Y, Ciceri F, Diez-Martin JL, Arat M, Sica S, Rovira M, Aljurf M, Tischer J, Savani B, Ruggeri A, Nagler A, Mohty M. Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT. J Hematol Oncol. 2021 May 28;14(1):84. doi: 10.1186/s13045-021-01094-2. PubMed 34049582 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2019 (actual). Primary completion is estimated for Nov 2026, 84 months after the start.

Of 227 non-industry phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 116. This study's planned 84 months is above that.

Counting every sponsor, half of 279 studies reached it within 65 months; a quarter within 39 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2020
First posted
Jan 18, 2020
StartActual
Nov 14, 2019
Primary completionEst.
Nov 22, 2026
CompletionEst.
Nov 26, 2026
Last update
Apr 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04232241
Collaborators
GKM Gesellschaft für Therapieforschung mbH, Staburo GmbH
Responsible party
Sponsor
First posted
Jan 18, 2020
Start date
Nov 14, 2019
Primary completion
Nov 22, 2026 (estimated)
Completion
Nov 26, 2026 (estimated)
Last update
Apr 22, 2025

Study contacts

Nicolaus Kröger, Prof. Dr.
principal investigator · University Medical Center Hamburg-Eppendorf, Department of Stem Cell Transplantation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion